View Complete Prescribing Data OPDIVO® (nivolumab) is indicated to the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed soon after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or right after 3 or maybe